Title: The Use of High Dosages of Transdermal Buprenorphine for Pain Management in Palliative Cancer Patients: A Case Study
Authors: Clement, Paul ×
Beuselinck, Benoit
Van Beek, Karen
Mertens, Georgette
Cornelissen, Paul
Menten, Johan #
Issue Date: 29-Mar-2013
Publisher: S. Karger AG
Series Title: Case Reports in Oncology vol:6 pages:169-173
Abstract: Pain is a prevalent condition in patients with cancer, particularly in advanced stages of cancer. Although strong opioids are the mainstay of cancer pain management protocols,patients are often undertreated. Transdermal buprenorphine is currently available for the treatment of moderate to severe cancer pain and severe pain which does not respond to nonopioid analgesics; patch doses of 35, 52.5 and 70 μg/h are available (applied for up to 96 h), with no more than 2 transdermal patches at the same time, regardless of the strength.
To date, there are no published reports in the literature of the use of high-dose transdermal buprenorphine (>140 μg/h). Herein, we present 2 cases of palliative cancer patients who received transdermal buprenorphine at doses titrated up to 210 and 175 μg/h, respectively, for the management of pain. Transdermal buprenorphine titrated to doses >140 μg/h provided adequate pain control and was well tolerated. Future studies to confirm these initial
observations are warranted.
ISSN: 1662-6575
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Radiotherapy
Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.